Roche
Search results
Genentech's legacy and future aspirations are built on the belief that the boundaries of science are meant to be broken and that we can solve some of the hardest biomedical challenges plaguing humankind. Learn More. Quick Links. Advancing Inclusive Research. Patient Financial Support.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 45 years. Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases.
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.
Genentech has multiple medicines for serious and life-threatening medical conditions. Access information and resources on each of our medicines.
Genentech is a leading biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Its transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.
Pioneering together for a cancer-free tomorrow. Genentech is committed to defeating cancer. Building upon our legacy as pioneers in oncology, we're boldly innovating beyond the science and envision a better future for every cancer patient, caregiver, and provider. We can't do it alone.
early days of Genentech enter the story, including Robert Crea, Herb Heyneker, Peter Seeburg, John Shine, Axel Ullrich and David Goeddel. Boyer and Swanson first decided to clone synthetic ...
Jan 25, 2023 · On 22 December 2022, the US Food and Drug Administration (FDA) granted accelerated approval to mosunetuzumab-axgb, Genentech’s full-length bispecific monoclonal antibody that targets the B cell...
Dec 5, 2022 · Genentech (South San Francisco, CA, USA; US) HER2-positive breast cancer: 2020 (EU & US) Polivy (polatuzumab vedotin), ADC comprising a humanized IgG1, produced in CHO cells, targeting a component of the B cell receptor (CD79b) conjugated to monomethyl auristatin E (MMAE). Roche (Grenzach-Wyhlen, Germany) Genentech (South San Francisco, CA, USA)
Learn how Genentech is continuing to go forward in the precision medicine space with real-world evidence, education for policymakers, development of molecules, education on biomarker testing and more.
